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OBJECTIVE — We describe a maturity-onset diabetes of the young (MODY) case with mu-
tations involving both HNF4A and HNF1A genes.
RESEARCH DESIGN AND METHODS — A male patient was diagnosed with diabetes
at age 17; the metabolic control rapidly worsened to insulin requirement. At that time no
relatives were known to be affected by diabetes, which was diagnosed years later in both the
parents (father at age 50 years, mother at age 54 years) and the sister (at age 32 years, during
pregnancy).
RESULTS — The genetic screening showed a double heterozygosity for the mutation
p.E508KintheHNF1A/MODY3geneandthenovelvariantp.R80QintheHNF4A/MODY1gene.
The genetic testing of the family showed that the father carried the MODY3 mutation while the
mother, the sister, and her two children carried the MODY1 mutation.
CONCLUSIONS — MODY1 and MODY3 mutations may interact by chance to give a more
severe form of diabetes (younger age at presentation and early need of insulin therapy to control
hyperglycemia).
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M
aturity-onset diabetes of the
young (MODY) (MIM #606391)
is a genetically and clinically het-
erogeneous group of disorders character-
ized by early onset of noninsulin-
dependent diabetes and autosomal
dominant inheritance. At least seven
types of MODY have been identiﬁed (1).
Heterozygous mutations of the gene en-
coding the hepatocyte nuclear factor 1-
(HNF1A/MODY3) are the most common
causes of MODY in northern Europe and
a frequent cause of MODY in many other
populations. Mutations in the HNF4
gene (HNF4A/MODY1) are considerably
less common (2,3).
We describe the clinical history of a
family, including a case in which double





The patient LN was found hyperglycemic
at age 17 years (fasting blood glucose
[FBG]120–150mg/dl).Previousmedical
history was negative. Birth weight was
4.350 kg, and no history of neonatal
hypoglycemia was reported. After a
6-month nutritional therapy, insulin was
required (two NPH injections/day). After
2 years, a remission took place; the pa-
tientstoppedinsulinandwastreatedwith
sulfonylureas for the following 10 years,
when insulin was again required. Mark-
ersofautoimmunediabetesisletcellan-
tibody (ICA)/GAD antibody (GADA)
(immunoﬂuorescenceandELISA;Euro-
immun, Lu ¨beck, Germany) were re-
peatedly negative, and fasting levels of
C-peptide and insulin (Electrochemilu-
minescentimmunoassay;RocheDiagnos-
tics, Penzberg, Germany) remained
detectable throughout the observation
period (C-peptide 1.1–2.4 ng/ml). The
patient has been on insulin therapy since
2006 (rapid analog before breakfast and
lunch, premixed analog before dinner)
with good metabolic control (A1C 6.8–
7.2%), without evidence of micro- and
macrovascular complications.
The relatives
LNs younger sister was referred for hy-
perglycemia at screening (133 mg/dl) at
week 8 of her ﬁrst pregnancy (age 32
years). Her medical history was negative,
apart from a single record of raised FBG
(115 mg/dl) 1 year earlier. The sister’s
birth weight was 3.8 kg, and no history of
neonatal hypoglycemia was reported.
A1C was 6.7% (normal values 5.9%),
60-minglucoseduringa50-gglucosetol-
erance test was 205 mg/dl. ICA/GADA
were negative; C-peptide levels (fasting/
postprandial) were 1.7/2.4 ng/ml. During
pregnancy, basal-bolus insulin was re-
quired. After delivery (caesarean section
atweek38),FBGnormalizedwithdietary
restrictions, but a 75-g oral glucose toler-
ance test was positive (120-min blood
glucose 216 mg/dl). A second pregnancy,
2 years later, (caesarean section at week
40), again required basal-bolus insulin.
A1C and fasting and postprandial glyce-
mia remained in the normal range
(5.9% and 140 mg/dl at 2 h) through
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macrosomic (male 4.350 kg; female
4.100kg,atweek38and40,respectively)
and hypoglycemic (26 and 37 mg/dl at
birth)andneededprolongedpostnatalin-
travenous glucose infusion (7 and 10
days).
Thesiblings’father(age57years)had
been diagnosed with type 2 diabetes at
age 50, and we found high FBG in the
mother (133 and 135 mg/dl) during in-
vestigations (age 54 years). Considering
the whole family phenotype, the negativ-
ity of autoimmune markers in all case
subjects, and LNs maintained endoge-
nous insulin after 19 years of diabetes, we
investigated the family for the presence of
monogenic diabetes.
RESULTS— All subjects gave written
informedconsent.Themolecularanalysis
of the HNF1A/MODY3 gene in the two
siblings by denaturing high-performance
liquid chromatography and sequencing
of exons 1–10 and ﬂanking regions iden-
tiﬁed the missense mutation p.E508K
(c.1522GA, exon 8) in the brother,
whichwasabsentinthesister.Thefurther
screening of exons 1d-10, ﬂanking se-
quences, and the P2 promoter of HNF4A/
MODY1 gene revealed the novel variant
p.R80Q (c.239GA, exon 2) in both sib-
lings (Fig. 1) (supplementary Table 1 in
the online appendix available at http://
care.diabetesjournals.org/cgi/content/
full/dc10-0561/DC1). The genetic testing
ofthefamilyindicatedthatthefather(I-2)
carried the MODY3 variant, and the
mother (I-1) carried the MODY1 variant,
and so did both the children of the sister
(III-2 and III-3). No variant was demon-
strated in LNs daughter (III-1) or in the
uncle (I-3), who were both free of
diabetes.
The novel p.R80Q caused a replace-
ment of an amino acid conserved across
mammalian species. Using PolyPHEN (4)
and SIFT (5) software for predicting the
potential pathogenic effect, the variant
was likely to be disease-causing muta-
tions. The variant was absent in 144 nor-
mal chromosomes of Italian subjects.
CONCLUSIONS — We describe a
case with double heterozygosity for mu-
tations involving both the HNF4A/
MODY1 and HNF1A/MODY3 genes. The
proband carrying both variants shows a
more severe form of diabetes compared
with the family members carrying only
one mutation.
The p.R80Q variant found in HNF4A
gene has not been reported previously. A
different mutation at codon 80 (p.R80W)
has been recently detected in a patient
withdiazoxide-responsivehyperinsuline-
mic hypoglycemia (6). Our data conﬁrm
that this arginine is an important residue
for the HNF4 function. Although no
functionalinvitroanalysiswasperformed
to identify the pathogenicity of this muta-
tion, its role is supported by neonatal
macrosomia and hypoglycemia (after a
pregnancy with optimal glucose control)
in both children inheriting the p.R80Q
Figure 1—A: Pedigree and genotypes of the family, showing that the proband LN (II-1) carries both the variants, while his parents (I-1, I-2), his
sisterEN(II-2),andthesister’schildren(III-2,III-3)carryasinglemutationineitherHNF4AorHNF1Agene.Filledsymbolsidentifysubjectswith
diabetes,diagonalhatchingrepresentssubjectswithneonatalmacrosomiaandhypoglycemia,emptysymbolsidentifyhealthyindividuals,thearrow
indicates the proband. Additional clinical data are also reported; age is at diagnosis of diabetes (DM). B: Representative chromatograms of the
HNF4Ap.R80QandHNF1Ap.E508Kmutationsidentiﬁedinthefamily.IRCP,immunoreactiveC-peptide;IS,insulinsensitivity;na,notapplicable;
nd, not done; WC, waist circumference.
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homeostasis model assessment–insulin
resistance(HOMA-IR)inthefamilymem-
bers, the absence of mutation in normal
subjects, the amino acid conservation
through evolution, and the bioinformatic
predictions.
The p.E508K mutation detected in
HNF1A gene has been previously re-
ported as a MODY3-causing mutation.
Thelateonsetofdiabetesoftheproband’s
father carrying this mutation is consistent
with the milder phenotype reported in
patients with missense mutations in ex-
ons 8–10 that affect only the HNF1A(A)
isoform (8). Though the coexistence of
type 2 diabetes cannot be absolutely ex-
cluded in LN’s father on the basis of the
phenotype (overweight, waist circumfer-
ence, and borderline HOMA-IR), the ab-
sence of hyperglycemia in LN’s older
wild-type uncle with similar phenotype
is consistent with a primary role of
mutation.
The combined effect of two variants
may explain the more severe diabetes in
the proband. Similar effects were shown
in subjects with double mutations in
HNF1AandtheA3243Ginmitochondrial
DNA (9). HNF4 has a key role in regu-
lating the islet transcriptional networks
and, in combination with HNF1, has
been proposed to form a functional regu-
latory loop in adult -cell (10). The clin-
ical features of our patient with double
heterozigosity support this hypothesis.
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